Skip to main content
. 2018 Oct 4;7(20):e010013. doi: 10.1161/JAHA.118.010013

Figure 1.

Figure 1

Antibody validation. A, Western blot showing transforming growth factor β receptor II (Tgfbr2) protein expression in the protein lysates from nontransgenic (Ntg) hearts and cardiomyocyte‐specific Tgfbr2‐ablated mice (R2CD). B, Validation of antibodies for phospho‐SMAD3 (p‐SMAD3, phospho‐TAK1 (p‐TAK1) and phospho‐p38 (p‐p38) after treatment of fibroblasts with TGF‐β (+). GAPDH indicates glyceraldehyde 3‐phosphate; SMAD3, small mothers against decapentaplegic homolog 3; TAK1, transforming growth factor beta–activated kinase 1; TGF‐β, transforming growth factor beta.